通过抑制炎症,调节氧化应激和调节铁
Liu Cao1, Xiaoqing Tang1, Ximin Wang1
1Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Chinese Medicine, Zhongshan, 528400, China.
通过改善肠道屏障功能,调节肠道微生物群,减少炎症,减轻氧化应激和铁.
科学领域:
- 胃肠病学
- 药理学
- 免疫学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,治疗选择有限.
- 目前的治疗方法往往具有显著的副作用和可变的疗效.
- 了解新的治疗机制对于开发更好的UC治疗至关重要.
研究的目的:
- 在小鼠模型中系统评估Psoralen (PSO) 对性结肠炎 (UC) 的治疗效果.
- 调查PSO作用的潜在机制,重点是肠道屏障功能,肠道微生物群,炎症,氧化应激和铁.
主要方法:
- 在小鼠中使用硫酸 (DSS) 诱导UC.
- 通过体重,疾病活性指数 (DAI),结肠长度和组织病理学来评估PSO的治疗疗效.
- 分析了肠道屏障完整性,肠道微生物组成,炎症性细胞因子,氧化应激标志物和与铁死相关的蛋白质.
主要成果:
- PSO显著改善了UC症状,改善了结肠长度和组织病理学.
- 通过调节密集结蛋白和降低透性来增强肠道屏障的完整性.
- PSO调节了肠道微生物群,抑制了炎症通路 (TLR4/MyD88/NF-κB,JAK2/STAT3),缓解了氧化应激,并抑制了铁.
结论:
- 在性结肠炎中,Psoralen具有显著的治疗潜力.
- 通过多目标机制发挥作用,包括增强肠道屏障,调节微生物群,抗炎作用,减轻氧化应激和铁.
- 对于未来的UC疗法开发来说,PSO是一个有前途的候选者.
更多相关视频
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
